valsartan has been researched along with Coronary Artery Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Amano, T; Harada, K; Ichimiya, S; Ishii, H; Kanashiro, M; Kobayashi, M; Kurebayashi, N; Marui, N; Murohara, T; Sone, T; Suzuki, S; Tsuboi, H; Uetani, T; Yoshikawa, D | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N | 1 |
| Dörffel, Y; Kappert, K; Kintscher, U; Kümmel, A; Martus, P; Marx, N; Schimkus, J; Schneider, A; Scholze, J; Stoppelhaar, M; Unger, T; Walcher, D; Winkler, R | 1 |
| Dohi, Y; Fujii, T; Hayashi, Y; Ishibashi, K; Kihara, Y; Kurisu, S; Okada, T; Okimoto, T; Otsuka, M; Tadehara, F; Yamamoto, H | 1 |
| Koide, M; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Fukuda, D; Sata, M; Takamoto, S; Yamamoto, T | 1 |
| Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF | 1 |
| Ikeda, N; Inoue, T; Komiyama, N; Kyo, S; Matsumoto, K; Nishimura, S; Suzuki, H | 1 |
| Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B | 1 |
| Cohn, JN; Duprez, DA; Florea, ND; Jones, K | 1 |
| Peters, S | 1 |
13 trial(s) available for valsartan and Coronary Artery Disease
| Article | Year |
|---|---|
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Revascularization; Prospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Valsartan | 2017 |
Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypertension; Image Interpretation, Computer-Assisted; Imidazoles; Long-Term Care; Male; Middle Aged; Tetrazoles; Ultrasonography, Interventional; Valine; Valsartan | 2013 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Systole; Treatment Outcome; Valsartan | 2016 |
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Interleukin-6; Lipids; Male; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2010 |
Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Endpoint Determination; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Prospective Studies; Stents; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Prospective Studies; Risk Factors; Stroke; Survival Rate; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan | 2005 |
Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Patient Selection; Protective Agents; Renal Artery Obstruction; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2006 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Intercellular Adhesion Molecule-1; L-Selectin; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2007 |
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan | 2007 |
Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Sex Factors; Stents; Tetrazoles; Valine; Valsartan | 2008 |
3 other study(ies) available for valsartan and Coronary Artery Disease
| Article | Year |
|---|---|
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes | 2013 |
The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Coronary Artery Disease; Coronary Vessels; Heart Transplantation; Male; Mice; Mice, Inbred DBA; Tetrazoles; Valine; Valsartan | 2005 |